A High-Throughput Screening Assay for NKCC1 Cotransporter Using Nonradioactive Rubidium Flux Technology

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• The NKCC1 cotransporter is a potential therapeutic target for numerous disorders.
• Electrophysiological techniques for NKCC1 screening are slow, costly, and not amenable to high-throughput screening.
• Existing assays, like thallium flux assays, can suffer from toxicity and generate false results.

Purpose of the Study:

• To develop a robust, nonradioactive, high-throughput screening (HTS) assay for the NKCC1 cotransporter.
• To establish a functional assay for NKCC1 that is sensitive, specific, and automatable.
• To provide a viable alternative to existing electrophysiological and thallium flux assays.

Main Methods:

• Development of a nonradioactive rubidium flux assay using human embryonic kidney (HEK) cells expressing NKCC1.
• Optimization of the assay to achieve an eightfold window of detection.
• Validation of the assay's robustness using Z' values (0.9 for manual, 0.7 for automated).

Main Results:

• The developed assay demonstrated high sensitivity and specificity for NKCC1.
• The assay achieved a Z' score of 0.9 (manual) and 0.7 (automated), indicating robustness and amenability to automation.
• The assay successfully screened compound libraries in a high-throughput format.

Conclusions:

• The novel rubidium flux assay is a reliable and efficient method for NKCC1 screening.
• This assay overcomes the limitations of traditional electrophysiological and thallium flux methods.
• The developed HTS assay provides a valuable tool for identifying novel therapeutics targeting NKCC1 for diverse disorders.